After several years of restructuring, Switzerland-based Clariant is looking to develop its second-generation bioethanol technology – which uses crops to create biofuel – as a direct result of its $2.5 billion buyout of Sued-Chemie. The company, purchased in 2011, focuses on catalyst making and has reportedly allowed for Clariant to utilize more advanced technology and research. The company has now announced new testing of that technology in efforts to strengthen its stance against rivals Royal DSM NV and Novosymes A/S. Testing is reportedly going on in Munich, Germany. The company is also planning to sell three of its commodity-chemical units for $1.3 billion to re-invest profits into the project. Clariant says the deals will be finalized by the end of this September.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC v. Meta Trial Turns to Market Definition
Apr 28, 2025 by
CPI
Marriott to Acquire CitizenM for $355 Million, Expanding Urban Lifestyle Offerings
Apr 28, 2025 by
CPI
Thomson Reuters Urges Third Circuit to Block Ross Intelligence’s Copyright Appeal
Apr 28, 2025 by
CPI
Merck KGaA to Acquire SpringWorks for $3.9 Billion
Apr 28, 2025 by
CPI
Federal Judge Dismisses Mario Chalmers’ Antitrust Lawsuit Against NCAA Over NIL Rights
Apr 28, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece